Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines about artificial intelligence. Everyone's talking about AI right now. But see, I've been talking about it for years.

I call it my AI Retirement Playbook. I recommend you check it out now.

Henry Fuchs Biography and Net Worth

Insider of BioMarin Pharmaceutical

Henry J. Fuchs, M.D., joined BioMarin in March 2009 and currently serves as our President of Worldwide Research & Development. From December 2009 to October 2016, Dr. Fuchs served as our Executive Vice President and Chief Medical Officer. From March 2009 to December 2009, Dr. Fuchs served as our Senior Vice President and Chief Medical Officer. From September 2005 until December 2008, Dr. Fuchs served as Executive Vice President and Chief Medical Officer for Onyx Pharmaceuticals, a biopharmaceutical company. Dr. Fuchs served as Chief Executive Officer of Ardea Biosciences, Inc. from January 2003 until June 2005. Dr. Fuchs first joined Ardea Biosciences, Inc. as Vice President, Clinical Affairs in October 1996 and was appointed President and Chief Operating Officer in November 2001. From 1987 to 1996, Dr. Fuchs held various positions at Genentech, Inc. where, among other responsibilities, he led the clinical program that resulted in the approval of Pulmozyme, a therapeutic for cystic fibrosis. Dr. Fuchs was also responsible for the Phase III development program that led to the approval of Herceptin to treat metastatic breast cancer. Dr. Fuchs received an M.D. degree from George Washington University and a B.A. degree in biochemical sciences from Harvard University. Dr. Fuchs is currently a director of Mirati Therapeutics, a public biopharmaceutical company. He was on the board of Ardea Biosciences, Inc. from 1996 until its acquisition by AstraZeneca PLC in 2012, and he was also on the board of Genomic Health, Inc. from 2013 until its acquisition by Exact Sciences in 2019.

What is Henry J. Fuchs' net worth?: The estimated net worth of Henry J. Fuchs is at least $13.93 million as of March 5th, 2024. Dr. Fuchs owns 212,117 shares of BioMarin Pharmaceutical stock worth more than $13,927,602 as of December 21st. This net worth estimate does not reflect any other assets that Dr. Fuchs may own. Additionally, Dr. Fuchs receives a salary of $1,410,000.00 as Insider at BioMarin Pharmaceutical. Learn More about Henry J. Fuchs' net worth.
How old is Henry J. Fuchs?: Dr. Fuchs is currently 66 years old. There are 6 older executives and no younger executives at BioMarin Pharmaceutical. Learn More on Henry J. Fuchs' age.
What is Henry J. Fuchs' salary?: As the Insider of BioMarin Pharmaceutical Inc., Dr. Fuchs earns $1,410,000.00 per year. The highest earning executive at BioMarin Pharmaceutical is Mr. Alexander Hardy, President, CEO & Director, who commands a salary of $1,720,000.00 per year. Learn More on Henry J. Fuchs' salary.
How do I contact Henry J. Fuchs?: The corporate mailing address for Dr. Fuchs and other BioMarin Pharmaceutical executives is 770 Lindaro Street, San Rafael CA, 94901. BioMarin Pharmaceutical can also be reached via phone at (415) 506-6700 and via email at [email protected]. Learn More on Henry J. Fuchs' contact information.
Has Henry J. Fuchs been buying or selling shares of BioMarin Pharmaceutical?: Henry J. Fuchs has not been actively trading shares of BioMarin Pharmaceutical during the last quarter. Most recently, Henry J. Fuchs sold 35,341 shares of the business's stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $85.18, for a transaction totalling $3,010,346.38. Following the completion of the sale, the insider now directly owns 212,117 shares of the company's stock, valued at $18,068,126.06. Learn More on Henry J. Fuchs' trading history.
Who are BioMarin Pharmaceutical's active insiders?: BioMarin Pharmaceutical's insider roster includes Jeffrey Ajer (EVP), Mark Alles (Director), Jean Bienaime (CEO), George Davis (EVP), Willard Dere (Director), Henry Fuchs (Insider), Michael Grey (Director), Charles Guyer (EVP), V. Lawlis (Director), Richard Meier (Director), Brian Mueller (CFO), David Pyott (Director), and Dennis Slamon (Director). Learn More on BioMarin Pharmaceutical's active insiders.
Are insiders buying or selling shares of BioMarin Pharmaceutical?: In the last twelve months, insiders at the biotechnology company sold shares 15 times. They sold a total of 196,207 shares worth more than $16,544,419.92. The most recent insider tranaction occured on November, 12th when EVP Charles Greg Guyer sold 5,278 shares worth more than $350,300.86. Insiders at BioMarin Pharmaceutical own 1.9% of the company. Learn More about insider trades at BioMarin Pharmaceutical.
Information on this page was last updated on 11/12/2024.

Henry J. Fuchs Insider Trading History at BioMarin Pharmaceutical

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/5/2024	Sell	35,341	$85.18	$3,010,346.38	212,117
8/10/2023	Sell	12,000	$90.43	$1,085,160.00	176,187
7/20/2020	Sell	126,389	$130.00	$16,430,570.00	104,245
7/13/2020	Sell	23,011	$130.00	$2,991,430.00	102,995
4/24/2020	Sell	20,000	$95.88	$1,917,600.00	109,014
4/20/2020	Sell	17,213	$90.00	$1,549,170.00	122,656
3/25/2019	Sell	5,932	$87.86	$521,185.52	130,468
3/18/2019	Sell	9,597	$94.09	$902,981.73	133,061
3/4/2019	Sell	2,196	$95.00	$208,620.00	142,504
8/27/2018	Sell	25,000	$99.50	$2,487,500.00	142,667
8/24/2018	Sell	12,500	$99.00	$1,237,500.00	142,667
6/14/2018	Sell	31,000	$90.00	$2,790,000.00	157,167
4/2/2018	Sell	10,000	$80.12	$801,200.00	160,026
1/2/2018	Sell	15,000	$89.23	$1,338,450.00
9/15/2017	Sell	15,000	$90.50	$1,357,500.00	141,422
6/19/2017	Sell	15,000	$90.00	$1,350,000.00	141,422
2/24/2017	Sell	15,000	$87.99	$1,319,850.00	128,442
8/26/2016	Sell	15,000	$95.06	$1,425,900.00	128,878
5/26/2016	Sell	15,000	$87.81	$1,317,150.00	130,914
6/5/2015	Sell	1,864	$122.32	$228,004.48
5/18/2015	Sell	1,864	$124.78	$232,589.92
5/13/2015	Sell	1,434	$121.37	$174,044.58
5/11/2015	Sell	2,869	$121.64	$348,985.16
3/16/2015	Sell	41,315	$123.57	$5,105,294.55
11/10/2014	Sell	20,000	$86.55	$1,731,000.00
8/5/2014	Sell	10,000	$65.00	$650,000.00
9/5/2013	Sell	10,000	$70.00	$700,000.00
7/1/2013	Sell	10,000	$60.00	$600,000.00
6/3/2013	Sell	1,098	$58.32	$64,035.36
5/23/2013	Sell	20,609	$66.29	$1,366,170.61
9/4/2012	Sell	5,000	$37.76	$188,800.00

Henry J. Fuchs Buying and Selling Activity at BioMarin Pharmaceutical

BioMarin Pharmaceutical Company Overview

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Today's Range

Now: $65.66

$64.07

$66.27

50 Day Range

MA: $66.58

$61.93

$70.53

2 Week Range

Now: $65.66

$61.15

$99.25

Volume

3,974,318 shs

Average Volume

1,808,870 shs

Market Capitalization

$12.51 billion

P/E Ratio

39.32

Dividend Yield

N/A

Beta

0.29

Most People Are Dead Wrong.

From Brownstone Research | Ad

I call it my AI Retirement Playbook. I recommend you check it out now.

Henry Fuchs Biography and Net Worth

What is Henry J. Fuchs' net worth?

How old is Henry J. Fuchs?

What is Henry J. Fuchs' salary?

How do I contact Henry J. Fuchs?

Has Henry J. Fuchs been buying or selling shares of BioMarin Pharmaceutical?

Who are BioMarin Pharmaceutical's active insiders?

Are insiders buying or selling shares of BioMarin Pharmaceutical?